



Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events

Toshiaki Ohkuma¹ · Sanne A. E. Peters² · Mark Woodward^{1,2,3}

Received: 16 January 2018 / Accepted: 2 May 2018 / Published online: 20 July 2018
© The Author(s) 2018

Abstract

Aims/hypothesis Diabetes has been shown to be a risk factor for some cancers. Whether diabetes confers the same excess risk of cancer, overall and by site, in women and men is unknown.

Methods A systematic search was performed in PubMed for cohort studies published up to December 2016. Selected studies reported sex-specific relative risk (RR) estimates for the association between diabetes and cancer adjusted at least for age in both sexes. Random-effects meta-analyses with inverse-variance weighting were used to obtain pooled sex-specific RRs and women-to-men ratios of RRs (RRRs) for all-site and site-specific cancers.

Results Data on all-site cancer events (incident or fatal only) were available from 121 cohorts (19,239,302 individuals; 1,082,592 events). The pooled adjusted RR for all-site cancer associated with diabetes was 1.27 (95% CI 1.21, 1.32) in women and 1.19 (1.13, 1.25) in men. Women with diabetes had ~6% greater risk compared with men with diabetes (the pooled RRR was 1.06, 95% CI 1.03, 1.09). Corresponding pooled RRRs were 1.10 (1.07, 1.13) for all-site cancer incidence and 1.03 (0.99, 1.06) for all-site cancer mortality. Diabetes also conferred a significantly greater RR in women than men for oral, stomach and kidney cancer, and for leukaemia, but a lower RR for liver cancer.

Conclusions/interpretation Diabetes is a risk factor for all-site cancer for both women and men, but the excess risk of cancer associated with diabetes is slightly greater for women than men. The direction and magnitude of sex differences varies by location of the cancer.

Keywords Cancer · Diabetes · Meta-analysis · Sex differences · Systematic review

Abbreviations

APCSC Asia Pacific Cohort Studies Collaboration
RRR Ratio of RR

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00125-018-4664-5>) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

✉ Toshiaki Ohkuma
tohkuma@georgeinstitute.org.au

✉ Mark Woodward
mark.woodward@georgeinstitute.ox.ac.uk

¹ The George Institute for Global Health, University of New South Wales, Level 10, King George V Building, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia

² The George Institute for Global Health, University of Oxford, Le Gros Clark Building, South Parks Road, Oxford OX1 3QX, UK

³ Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA

Introduction

Cancer is the second leading causes of death in the world [1]. In 2015, there were 17.5 million incident cancer cases and 8.7 million cancer deaths globally, and it is estimated that one in four women and one in three men develop cancer during their lifetime [2]. The incidence of cancer is expected to increase in the next decades, emphasising the importance of efficient prevention and treatment of cancer worldwide.

The prevalence of diabetes has also grown rapidly. In 2015, one in 11 adults (415 million) were reported to have diabetes, five million deaths were attributed to diabetes, and 12% of global health expenditure was spent on diabetes and its

Research in context

What is already known about this subject?

- Diabetes has been associated with the risk of all-site, and some site-specific, cancers in several systematic reviews and meta-analyses
- There has been no systematic overview of the evidence available on sex differences in the association between diabetes and cancer

What is the key question?

- Does diabetes confer the same excess risk of cancer, overall and by site, in women and men?

What are the new findings?

- In this systematic review, with meta-analysis, of 121 cohorts, including more than 19 million individuals and over one million all-site cancer events, diabetes was associated with all-site cancer in both sexes, but with a 6% higher excess risk in women compared with men
- Diabetes was also associated with several site-specific cancers and conferred a significantly greater excess risk in women than men for oral, stomach and kidney cancer, and for leukaemia, but a lower excess risk for liver cancer
- The findings were broadly consistent for incident and fatal cancer

How might this impact on clinical practice in the foreseeable future?

- This study indicates the importance of a sex-specific approach to quantification of the role of diabetes in cancer prevention and treatment

complications [3]. Diabetes has been associated with the risk of all-site and some site-specific cancers in several systematic reviews and meta-analyses [4–13]. However, only a minority of these associations are based on robust supporting evidence without question of significant bias [14]. To date, there has been no systematic overview of the evidence available on sex differences in the association between diabetes and cancer. We have previously published compelling evidence that women with diabetes are at an increased risk of stroke [15], coronary heart disease [16] and dementia [17] compared with their male peers. We now question whether this is also true for cancer. In this study, we conducted the most comprehensive systematic review and meta-analysis, to date, to estimate the relative effect of diabetes on the risk of cancer in women compared with men.

Methods

Search strategy and selection criteria A systematic search was performed in PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>) on 23 December 2016 using a combined text word and medical subject heading search strategy (electronic supplementary material [ESM] Table 1). The reference lists of identified reports were also checked for other potentially relevant studies.

Observational cohort studies in general populations were included if they had provided relative risks (RRs), or equivalents, for the association between diabetes and cancer in both women and men. Studies were excluded if they had not

adjusted at least for age or did not provide information about the variability around the point estimate, or if they only had data for one sex. In case of duplicate reports from the same study, the study providing the longest follow-up or the highest number of cases was included. We also used individual participant data from the Asia Pacific Cohort Studies Collaboration (APCSC) [18], treated as two separate combinations of data from cohorts in Asia and cohorts from Australia or New Zealand, as in our previous work [15, 16]. One author (TO) did the search and extracted the data. Uncertainties regarding the inclusion or exclusion of articles and data extraction were discussed by all authors and resolved by mutual consent. The meta-analysis was done in accordance with the PRISMA criteria [19].

Data extraction and statistical analysis The primary endpoint was all-site cancer events (incident or, if this was all that was presented, mortal only). The secondary endpoints were all-site cancer incidence (i.e. omitting studies that only reported mortality), all-site cancer mortality and, for those cancers that could present in both sexes, site-specific cancer events, site-specific incidence and site-specific mortality. In sensitivity analysis we also compared all-site cancer incidence and mortality when restricting to the studies that reported both.

The primary metrics were the pooled adjusted RRs and the women-to-men ratios of RRs (RRRs) for individuals with diabetes vs those without diabetes. For each study, we extracted the sex-specific RRs and 95% CIs for individuals with diabetes vs those without diabetes, from which we estimated the RRRs and

95% CIs. To include the largest set of individuals and cancer endpoints, studies that reported either age-adjusted or multiple-adjusted (maximum-available-adjusted, i.e. the maximum set of adjustments available for each study) results were included in our primary analyses. In pooling multiple-adjusted results, the set of adjustments made were allowed to vary by study, but had to include at least one other risk factor for cancer, in addition to age [15, 16]. We obtained pooled estimates of sex-specific RRs across studies using random-effects meta-analyses applied on the \log_e scale. Individual studies were weighted according to the inverse variance of \log_e RRs. The same method was used to pool the RRRs.

The I^2 statistic was used to estimate the percentage of variability across studies due to between-study heterogeneity and the Q test was used to assess whether there was a significant lack of homogeneity. The possibility of publication bias was explored using funnel plots and Egger's and Begg's tests. Random-effects meta-regression analyses were used to test for differences between pre-assigned subgroups: study region (Asia or Non-Asia), year of baseline study (pre-1985 or 1986 onwards, and also examined as a continuous variable), ascertainment of diabetes (self-reported only or others), type of diabetes (type 1 or type 2, where studies which did not differentiate type were classified as type 2), level of adjustment (age-adjusted or multiple-adjusted), and study quality (the Newcastle–Ottawa Scale [20] [ESM Table 2], ≥ 7 or < 7 points, and also examined as a continuous variable). Post hoc, we also considered absolute risk difference, examined as a categorical and continuous variable) (ESM Table 3). A p value of below 0.05 was considered to be statistically significant in analyses for the primary analyses, i.e. all-site cancer. As many statistical tests

were envisaged, a p value of below 0.01 was taken to denote significance for site-specific cancers. All analyses were performed using Stata software (release 13; StataCorp, College Station, TX, USA).

Results

Of the 6371 articles identified through the systematic search, 371 articles qualified for full-text evaluation, and 107 articles provided summary data on the association between diabetes and the risk of cancer for both sexes [21–127]. In addition, 36 cohorts with individual participant data from the APCSC were included (Fig. 1).

Characteristics of the studies that reported the association between diabetes and all-site cancer incidence or mortality are shown in Table 1 and ESM Table 4. Data on all-site cancer were available from 47 studies, involving 121 cohorts, 19,239,302 individuals (not counting one study [25] that did not state the total number of participants), and 1,082,592 events (not counting one study [65] that did not state the total number of cancer events).

The maximum-available-adjusted pooled sex-specific RR estimates for combined fatal and non-fatal cancer associated with diabetes were 1.27 (95% CI 1.21, 1.32, $p < 0.001$) for women and 1.19 (1.13, 1.25, $p < 0.001$) for men (Fig. 2). The pooled women-to-men RRR was 1.06 (1.03, 1.09, $p < 0.001$, Fig. 3). The I^2 statistic for heterogeneity between studies was 66.7%, with no evidence of publication bias (Egger's test $p = 0.13$, Begg's test $p = 0.16$, ESM Fig. 1). The corresponding RRR was 1.06 (1.02, 1.11, $p = 0.005$) for type 1

Fig. 1 Flow chart of study selection




Table 1 Characteristics of the studies reporting on the association between diabetes and all-site cancer

Cohort	Country	Baseline study (years)	Follow-up (years)	No. participants (% women)	Mean age (years)	No. with diabetes (% women)	Type of diabetes	Ascertainment of diabetes	No. with outcome (% women)	I or M	Maximum adjustment available
Ragozzino et al [21] Sasazuki et al [22]	USA Japan (8 cohorts)	1945–1969 1984–1994	8.6 9.9	1135 (NR) 339,459 (54)	NR 35–103	1135 (NR) NR	Both Both	Measured Self-reported	120 (47) 33,022 (40)	I I	Age Age, area, Hx of cerebrovascular disease, CHD, smoking, alcohol consumption, BMI, physical exercise, green leafy vegetable consumption, coffee intake Age, year at cancer diagnosis
Gini et al [23]	Italy	2002–2009	3.7	32,247 (45)	65	32,247 (45)	T2	Hospital discharge diagnosis, exemption from medical charges, prescription	2069 (37)	I	Age, date of follow-up, date of birth
Berger et al [24]	Denmark	1996–2011	12.6	4,826,142 (50)	41.4	65,690 (47)	Both	Discharge diagnosis, claimed prescription	423,942 (51)	I	Age
Carstensen et al [25]	Australia, Denmark, Finland, Scotland, Sweden	1987–2000	8–38	NR 3,932,900 person-years (50)	NR	NR	T1	Diabetes registry, inpatient dataset	9149 (56)	I	Age, date of follow-up, date of birth
Diabetes II-to-Cancer [26] VHM&PP Study Cohort [27] Jee et al [28]	Germany Austria Korea	2003 1988–2001 1992–1995	3.3 8.4 10	26,742 (53) 140,813 (55) 1,298,385 (36)	64 43 46.9	26,742 (53) 4758 (48) 62,924 (33)	T2 Both Both	Physician's diagnosis Measured Self-reported, measured	1364 (44) 5212 (46) I: 53,833 (30) M: 26,473 (22)	I I I, M	Age Age (stratified), smoking, occupation, BMI Age, smoking, alcohol use Age, urbanisation level Age, calendar year
Wang et al [29] Hsu et al [30]	China Taiwan	2007–2013 2000–2007	6 5.9	327,268 (50) 14,619 (53)	59.8 50.2	327,268 (50) 14,619 (53)	T2 T1	Diabetes registry National health insurance research database	7435 (45) 760 (44)	I I	Age, urbanisation level Age, calendar year
Adami et al [31] Dankefer et al [32] NIH-AARP Diet and Health Study [33]	Sweden Israel USA	1965–1983 2002 1995–1996	5.2 11 11	51,008 (55) 2,186,196 (53) 494,867 (40)	NR 21–89 62.5	51,008 (55) 159,104 (53) 44,726 (33)	Both Both Both	Hospital discharge diagnosis Diabetes registry Self-reported	2417 (54) 128,720 (50) 82,251 (32)	I I I	Age Age, ethnic origin, socioeconomic status Age, BMI, race/ethnicity, education, marital health status, intake of red meat, white meat, fruits, vegetables, alcohol, and coffee, physical activity, smoking, multivitamin use
Xu et al [34] DRT [35] NDSS (T2DM) [36]	China Austria Australia	2004 2005 1997	3.7 8.7 5.8	36,379 (56) 5709 (47) 872,706 (47)	59 57.4 60.4	36,379 (56) 5709 (47) 872,706 (47)	T2 T2 T2	Diabetes registry Diabetes registry Diabetes registry	1205 (53) 525 (45) I: 70,406 (38) M: 26,333 (37)	I I I, M	Age Age, period in 5 year period groups Age, calendar year
NDSS (T1DM) [36]	Australia	1997	12	80,676 (48)	27.4	80,676 (48)	T1	Diabetes registry	I: 2079 (50) M: 593 (46)	I, M	Age, calendar year
Walker et al [37] MHS registry [38]	UK Israel	2001–2007 2000	7 8	80,838 (45) 100,595 (53)	55–79 61.6	80,838 (45) 16,721 (47)	T2 Both	Diabetes registry Healthcare service database	4285 (43) 8977 (43)	I I	Age, socioeconomic status Age, region, socioeconomic status, use of healthcare services a year prior to index date, BMI, Hx of CVD
CLUE II [39]	USA	1989	17	18,280 (57)	51.8	599 (56)	Both	Self-reported	I: 2481 (52), M: 907 (50)	I, M	Age, education, BMI, smoking, HT treatment, high cholesterol treatment, menopausal status (for women), Hx of use of oral contraceptives (for women), Hx of use of hormone replacement therapy (for women)
Zhang et al [40] Västerbotten Intervention Project [41] ARIC [42]	China Sweden USA	2002–2008 2003 1990–1992	6 8.3 ^a 15	7950 (52) 68,301 (51) 12,792 (55)	61.1 46.1 ^a 56.9	7950 (52) NR ^b 1125 (56)	T2 Both Both	Diabetes registry Measured Self-reported, prescription	366 (47) 2669 (53) I: 2637 (45) M: 887 (42)	I I I, M	Age, year of recruitment, smoking Age, race/ethnicity, ARIC study site, education, smoking status, cigarette-years smoked, BMI, waist circumference, postmenopausal hormone use (for women) Age, calendar year
Wideroff et al [43]	Denmark	1977–1989	5.7	109,581 (50)	Max: 64 F: 69	109,581 (50)	Both	Hospital discharge diagnosis	8831 (47)	I	Age, BMI, education, alcohol, smoking
APCSC (Asia) [18] APCSC (Australia and New Zealand) [18]	Asia (26 cohorts) ^c Australia, New Zealand (9 cohorts)	1961–1993 1989–1996	7 7	89,468 (46) 82,913 (52)	45 51	4621 (45) 3365 (44)	Both Both	Self-reported, measured Self-reported, measured	1800 (33) 2563 (41)	M M	Age, BMI, education, alcohol, smoking

Table 1 (continued)

Cohort	Country	Baseline study (years)	Follow-up (years)	No. participants (% women)	Mean age (years)	No. with diabetes (% women)	Type of diabetes	Ascertainment of diabetes	No. with outcome (% women)	I or M	Maximum adjustment available
Singapore Chinese Health Study [44]	Singapore	1999	10.1	7388 (52)	62	510 (47)	T2	Measured	388 (NR)	M	Age, dialect, interview year, education, smoking, alcohol, BMI
Poole Diabetes Study [45]	UK	1996–1998	5.25	736 (NR)	Max. 62.9 F: 65.9	368 (NR)	T2	Diabetes registry	45 (58)	M	Age (matched)
DERI Mortality Study [46]	Japan	1965–1979	24.4	1385 (60)	8.8	1385 (60)	T1	Diabetes registry	2 (50)	M	Age
Diabetes UK cohort study [47]	UK	1972–1993	28	T1:23,326 (NR) T2: 5040 (NR)	NR	23,326 (NR)	T1:23,326 (NR) T2: 5040 (NR)	Diabetes registry	T1: 89 (48), T2: 185 (32)	M	Age, calendar year, country ^d
JPHC [48]	Japan	1990, 1993	17.8	99,584 (54)	50.2	4286 (36)	Both	Self-reported	5288 (36)	M	Age, BMI, alcohol intake, smoking, Hx of hypertension, physical activity, area
Fresco study [49]	Spain (pool of 12 cohorts)	1991	10	55,283 (54)	56	8627 (47)	Both	Self-reported, measured	850 (36)	M	Age, smoking, BMI, SBP, TC, HDLC
NHIS-NSC [50]	Korea	2002–2003	9.7	29,807 (48)	NR	29,807 (48)	T2	National health insurance database	1759 (33)	M	Age
DECODE study [51]	Denmark, Finland, Italy, the Netherlands, Poland, Sweden, UK (17 cohorts)	1966–2004	15.8	44,655 (41)	53.4	3759 (48)	Both	Measured, self-reported	3235 (27)	M	Age, cohort, BMI, total cholesterol, BP, smoking
Tseng [52]	Taiwan	1995–1998	4.4	256,036 (54)	61.2	256,036 (54)	Both	National health insurance database	8098 (41)	M	Age
Piemonte Diabetes Register, Turin Population Register [53]	Italy	1991–1999	7.7	906,065 (NR)	20–	T1: 1608 (NR) T2: 29,656 (NR)	Both	Diabetes registry	26,251 (44)	M	Age, area of birth
Hisayama [54]	Japan	1988	16.9	2438 (57)	57.6	298 (45)	Both	Measured, self-reported	229 (37)	M	Age, BMI, total cholesterol, smoking, alcohol, family Hx of cancer, physical activity, dietary factors (daily intakes of total energy, total fat, salt, vitamin A, vitamin B1, vitamin B2, vitamin C, dietary fibre)
Forsass et al [55]	Finland	2003	5	5,147,349 in 1997, 5,300,484 in 2007	1–79	171,596 (54) in 1997 284,832 (49) in 2007	Both	Diabetes registry	54,461 (48)	M	Age
Fedeli et al [56]	Italy	2008	3	167,621 (45)	30–89	167,621 (45)	Both	Archives from subjects exempt from medical charges	5110 (35)	M	Age
HSE, SHeS [57]	UK	1994, 1995	17, 16	204,533 (55)	47	7199 (48)	Both	Self-reported, prescription	5571 (NR)	M	Age, smoking, BMI
Shen et al [58]	China	1998–2001	10.9	66,813 (66)	65–	9225 (66)	Both	Self-reported	6336 (55)	M	Age, alcohol use, smoking, exercise, housing and monthly expenditure, BMI
Weiderpass et al [59]	Sweden	1965–1983	6.7	144,427 (NR)	Max. 61.3 F: 65.8	144,427 (NR)	Both	Hospital discharge diagnosis	9661 (49)	M	Age, calendar year, comorbidity
CPS II [60]	USA	1982	26	1,053,831 (56)	NR	52,655 (50)	Both	Self-reported	120,221 (46)	M	Age, education, BMI, smoking, alcohol, vegetable intake, red meat intake, physical activity, aspirin use
Verona Diabetes Study [61]	Italy	1987	10	7148 (53)	67	7148 (53)	Both	Medical records, drug prescription database	641 (41)	M	Age
Sievers et al [62]	USA	1975	10	5131 (52)	15–	1266 (58)	T2	Measured	40 (50)	M	Age
2001 ENTRED study [63]	France	2001	5	9101 (NR)	66	9101 (NR)	Both	Self-reported	380 (NR)	M	Age
Allegheny County Type 1 Diabetes Registry [64]	USA	1965–1979	32.9	1075 (47)	10.9	1075 (47)	T1	Medical records	10 (NR)	M	Age, race
BRFSS [65]	USA	1992	5	9074 (NR)	18–	392 (NR)	Both	Self-reported	NR	M	Age
Wong et al [66]	UK	1985	5	4186 (49)	15–	4186 (49)	Both	Diabetes registry	131 (48)	M	Age
Bruno et al [67]	Italy	1988	5.7	1967 (57)	66.5	1967 (57)	T2	Medical record, prescription, sale records of reagent strips and syringes	107 (51)	M	Age, calendar period

Table 1 (continued)

Cohort	Country	Baseline study (years)	Follow-up (years)	No. participants (% women)	Mean age (years)	No. with diabetes (% women)	Type of diabetes	Ascertainment of diabetes	No. with outcome (% women)	I or M	Maximum adjustment available
Shaw et al [68]	Mauritius, Fiji, Nauru	1980, 1982, 1987	5	9179 (NR)	40.7	595 (53)	Both	Self-reported	97 (57)	M	Age, ethnicity, smoking ^f
Moss et al [69] Takayama study [70]	USA Japan	1980 1992	8.5 6.9	1772 (NR) 29,079 (54)	66.7 54.6	1772 (NR) 1217 (35)	Both Both	Medical records Self-reported	85 (55) 653 (39)	M M	Age, smoking, BMI, physical activity, years of education, Hx of HT, intake of total energy, vegetables, fat and alcohol
Chicago Heart Association Detection Project in Industry [71]	USA	1967–1973	12	20,755 (42)	35–64	643 (34)	Both	Self-reported	513 (38)	M	Age, BMI, smoking, SBP, serum cholesterol, education, treatment for HT

If mean values of age or follow-up year were unavailable, median or range was extracted

Wideroff et al was not included in meta-analysis as they did not provide sufficiently accurate CIs for RRs

Studies by Hsu et al, Adami et al, Walker et al, and the Japan Public Health Center-based prospective study, National Diabetes Services Scheme (type 1 diabetes), Takayama study and Västerbotten Intervention Project were excluded from the meta-analysis of primary outcome (all-site cancer) and included in either of the meta-analyses of all-site cancer incidence or mortality only, because of the overlapping of individuals with other studies

^a Derived from total cohort

^b Proportion with fasting glucose in the diabetic range (>6.9 mmol/l) was 2% for women and 3% for men

^c Korean Medical Insurance Corporation cohort was excluded


^d For type 1 diabetes, RRs for non-South Asians were extracted

^e RRs for non-insulin-treated diabetes were extracted

^f RRs for known diabetes were extracted

ARIC, Atherosclerosis Risk in Communities; BRFS, Behavioral Risk Factor Surveillance System; CLUE II, Give Us a Clue to Cancer and Heart Disease; CPS II, Cancer Prevention Study II; CVD, cardiovascular diseases; DECODE, Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe; DERI, Diabetes Epidemiology Research International; DRI, Diabetes Registry Iyrol; F, female; HDLC, HDL-cholesterol; HSE, Health Survey for England; HT, hypertension; Hx, history; I, incidence; JPHC, Japan Public Health Center-based prospective study; M, mortality; Ma, male; MHS, Maccabi Healthcare Services; NDSS, National Diabetes Services Scheme; NIH-AARP, National Institutes of Health-American Association of Retired Persons; NHIS-NSC, Korean National Health Insurance Service-National Sample Cohort; NR, not reported; SBP, systolic BP; SHeS, Scottish Health Survey; T1(DM), type 1 diabetes; T2(DM), type 2 diabetes; TC, total cholesterol; VHM&PP, The Vöralberg Health Monitoring and Promotion Programme; 2001–2006 ENTRED study, 2001–2006 National representative sample of people with diabetes study

Fig. 2 Maximum-available-adjusted RR for all-site cancer, comparing individuals with diabetes with those without diabetes by sex: **(a)** women; and **(b)** men. ANZ, Australia and New Zealand; ARIC, Atherosclerosis Risk in Communities; BRFSS, Behavioral Risk Factor Surveillance System; CLUE II, Give Us a Clue to Cancer and Heart Disease; CPS II, Cancer Prevention Study II; DECODE, Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe; DERI, Diabetes Epidemiology Research International; DRT, Diabetes Registry Tyrol; 2001 ENTRED study, 2001–2006 National representative sample of people with diabetes study; HSE, Health Survey for England; MHS, Maccabi Healthcare Services; NDSS, National Diabetes Services Scheme; NIH-AARP, National Institutes of Health-American Association of Retired Persons; NHIS-NSC, Korean National Health Insurance Service-National Sample Cohort; SHeS, Scottish Health Survey; VHM&PP, The Vorarlberg Health Monitoring and Promotion Programme






Fig. 3 Maximum-available-adjusted women-to-men RRR for all-site cancer, comparing individuals with diabetes with those without diabetes. For definition of study acronyms, please refer to Fig. 2 legend. ^aThe BRFSS did not report the total number of cancer events

diabetes and 1.06 (1.03, 1.09, $p < 0.001$) for type 2 diabetes, without evidence of significant heterogeneity by type of diabetes (p for interaction = 0.88, Fig. 4). Exclusion of 22 studies that provided only age-adjusted results had no appreciable effect on the pooled RR estimates (multiple-adjusted pooled RR in women 1.25 [1.17, 1.34], $p < 0.001$, RR in men 1.20 [1.11, 1.29], $p < 0.001$, RRR 1.06 [1.03, 1.10], $p < 0.001$, $I^2 = 48.9\%$) (ESM Figs 2 and 3).

The pooled RRR did not vary substantially by study region ($p = 0.45$), year of baseline study ($p = 0.54$ for categorical analysis, $p = 0.18$ for continuous analysis), ascertainment of diabetes ($p = 0.72$), level of adjustment ($p = 0.70$), quality of study ($p = 0.09$ for categorical analysis) or absolute risk difference between men and women ($p = 0.82$ for categorical analysis, $p = 0.99$ for continuous analysis), with the exception of continuous analysis for quality of study, $p = 0.01$) (Fig. 4 and ESM Fig. 4).

Secondary analyses of incidence (fatal or not) and mortality alone for all-site cancer are described in the ESM. The pooled women-to-men RRR for incidence was 1.10 (1.07, 1.13, $p <$

0.001) (ESM Fig. 5) and for mortality was 1.03 (0.99, 1.06, $p = 0.16$) (ESM Fig. 6).

In sensitivity analysis using only those studies which provided the RRs for both incidence and mortality, the pooled maximum-available-adjusted RRR was 1.12 (1.06, 1.17, $p < 0.001$) for all-site cancer incidence, and 1.10 (1.00, 1.21, $p = 0.04$) for all-site cancer mortality (ESM Fig. 7).

Data on site-specific cancer were available for 50 sites (50 sites for incidence and 29 sites for mortality) (<https://www.georgeinstitute.org/sites/default/files/esm-table.pdf>). Diabetes was associated with an increased risk of cancer in 43 sites in women and 42 sites in men, with a statistically significant increase ($p < 0.01$) in risk for those with diabetes in 20 sites in women and 18 sites in men (ESM Fig. 8). The pooled maximum-available-adjusted RRR was statistically significantly higher in women than men for kidney (1.11 [99% CI 1.04, 1.18], $p < 0.001$), oral (1.13 [1.00, 1.28], $p = 0.009$), stomach cancer (1.14 [1.07, 1.22], $p < 0.001$) and leukaemia (1.15 [1.02, 1.28], $p = 0.002$), whereas it was statistically significantly lower for liver cancer (0.88 [0.79, 0.99], $p = 0.005$)




Fig. 4 Subgroup analyses of women-to-men RRR for all-site cancer, comparing individuals with diabetes with those without diabetes. ^aSix studies were excluded because the baseline year bridged over 1985 (i.e. included both pre-1985 and 1986 onwards). ^bResults using multiple adjustment were used when available and age-adjusted otherwise, as in Fig. 3. ^cTen studies were excluded because absolute risks for men and women were unavailable

(Fig. 5). Separate results for incidence and mortality by site of cancer are described in the ESM (ESM Figs 5, 6, 9–24).

Discussion

This systematic review, with meta-analysis, of 121 cohorts including more than 19 million individuals and over one million all-site cancer events, demonstrated that diabetes was associated with a 6% higher excess risk of all-site cancer in women than men. Diabetes was associated with several site-specific cancers and conferred a significantly greater excess risk in women than men for oral, stomach and kidney cancer and for leukaemia, but a lower excess risk for liver cancer. The findings were broadly consistent for incident and fatal cancers and across a wide range of prespecified subgroups.

Our findings are in agreement with a previous meta-analysis, which found that the risk of all-site cancer incidence and mortality was significantly increased in both sexes [4]. However, this previous meta-analysis was about a tenth of the size of the current study, and included single-sex studies, and therefore was not able to reliably quantify sex differences as they could have been explained by differences in methods,

confounders adjusted for, and the background risks between studies of women and men alone.

As we found some evidence to suggest that the women-to-men RRRs tended to be smaller in studies of lower quality (Fig. 4 and ESM Fig. 4), our results may underestimate any true sex difference. A significant degree of heterogeneity was also observed between studies conducted in and outside Asia with regards to all-site cancer mortality (ESM Fig. 19). However, we did not find heterogeneity between regions for our primary outcome, nor for the other secondary outcomes (all-site cancer incidence), and thus we speculate that this may be a chance finding consequent to the high number of statistical tests conducted.

Although we found a slightly higher women-to-men RRR for cancer incidence than cancer mortality, the finding may be explained by chance differences between the included studies, as almost identical pooled RRR estimates were obtained in the sensitivity analysis restricted to five studies which provided the sex-specific RRs for both incidence and mortality from the same study.

With regard to cancer at specific sites, previous meta-analyses have yielded inconsistent results of increased (stomach [5], lung [6], kidney [7]), similar (oesophagus [8], colorectum [9], pancreas [10], bladder [11], thyroid [12]) or decreased (liver [13]) excess risk of cancer associated with diabetes in women compared with men. However, unlike our methods, these analyses included single-sex studies as well as studies among both women and men.

There are several possible explanations for the excess risk of cancer conferred by diabetes in women than men. One possible mechanism is poor glycaemic control in women with diabetes compared with men with diabetes [128, 129]. Hyperglycaemia may have carcinogenic effects by causing DNA damage [130], which could result from increased oxidative stress due to hyperglycaemia [130] or from hyperglycaemia itself [131]. Historically, women were likely to be undertreated or receive less intensive care compared with men [128, 132]. Further, a recent study showed that adherence to glucose-lowering medication was lower in women than men [133]. As such, the carcinogenic effects of hyperglycaemia may be enhanced in women and subsequently lead to an increased cancer risk compared with men. Alternatively, cumulative exposure to insulin resistance and subsequent hyperinsulinaemia may be longer in women compared with men. The average duration of impaired glucose tolerance or impaired fasting glucose has been found to be more than 2 years longer in women than men [134], suggesting that women may have more exposure to, often untreated, hyperinsulinaemia in the prediabetic state. Hyperinsulinaemia promotes cancer cell proliferation by stimulating the insulin receptor directly and insulin-like growth factor-1 indirectly [135]. Another factor that may, to some extent, explain the smaller RR for incidence of all-site cancer in men compared with women is the apparent protective effect of diabetes on prostate cancer in




Fig. 5 Maximum-available-adjusted pooled women-to-men RRR for cancer at each site, comparing individuals with diabetes with those without diabetes

men with diabetes [136]. Sex-specific cancers or site-specific cancers in which diabetes conferred greater or lower excess risk in women than men may also account for the association, although the degree of contribution cannot be determined from our analyses. In addition to sex difference for all-site cancer, we found also that diabetes conferred a significantly greater RR in women than men for oral, stomach and kidney cancer and for leukaemia, but a lower RR for liver cancer. The underlying mechanisms for sex differences in each specific association are not clear. However, unmeasured confounding factors specific to each site, such as *Helicobacter pylori* infection for stomach cancer [137] and hepatitis virus infection for liver cancer [138], might be involved. However, the literature around mechanisms underpinning the sex differences in site-specific cancers is scant and further studies are required to confirm and clarify these sex differences in site-specific associations. Finally, the studies in our analyses were not adjusted for female-specific factors including pregnancy, menopausal status and use of hormone replacement therapy that have also been associated with diabetes [139] and cancer [140].

We quantified sex differences based on RRs rather than risk differences. This might introduce a statistical artefact, in which the generally higher absolute risk for cancer in men, and the same risk difference subsequent to diabetes in each sex, would translate to a greater relative risk in women than men. However, this would require that risks of cancers associated with diabetes are additive rather than multiplicative, which is not generally considered to be the case in epidemiology. Indeed, RRs are much more commonly reported than risk differences in both epidemiological studies and clinical trials. Also, unlike risk differences, RRs are typically fairly stable across populations with different background risks, which make them suitable for summarisation of effects in meta-analyses. Furthermore, our previous meta-analyses on risk factors for cardiovascular diseases demonstrated that detection of a female disadvantage in RRs is not inevitable when men have higher absolute risk [141, 142]. We thus believe that the use of RRs in the present analyses is both practical and justifiable.

The strengths of this meta-analysis are its size and the inclusion of studies on the sex-specific effects of diabetes on all-

site cancer and 50 site-specific cancers, which enabled us to conduct the most comprehensive analyses to date on the sex-specific effects of diabetes on cancer risk. To limit the risk of bias, we only included cohort studies that were conducted in men and women and had adjusted for at least age. Limitations of this study are inherent to the use of published data and the heterogeneity between studies in ascertainment of diabetes, study design and duration, endpoint definition and degree of adjustment for confounders. Nevertheless, a range of subgroup analysis provided broadly consistent results. However, as we compared women and men from within the same study, any effect of differences in methods between studies is likely to have affected women and men similarly. We therefore assume that the sex comparisons reported in this analysis are still valid. Second, the lack of data on duration of diabetes and the degree of glycaemic control precluded more detailed analyses on the effect of diabetes on the risk of cancer. Third, as this meta-analysis largely used published data, endpoint definition varied across the studies. Fourth, in analysis of all-site cancer, the women-to-men RRRs depend not only on the strengths of the RRRs of site-specific cancers (as illustrated by Fig. 5), but also on the relative incidence of site-specific cancers, which varies considerably between populations. This is likely to be a key factor in the high between-study heterogeneity we show in Fig. 3. Finally, studies generally did not adjust for obstetric and gynaecological history and unmeasured confounding is likely in the current estimates. However, confounding is likely to have been non-differentially distributed between women and men from the same study and we therefore assume that it had only a negligible effect on the reported associations.

In conclusion, diabetes is a risk factor for all-site cancer in both sexes, with a stronger effect in women than men. Sex differences varied across the location of the cancer, heightening the importance of a sex-specific approach to quantification of the role of diabetes in cancer research, prevention and treatment. Further studies are needed to clarify the mechanisms underlying the sex differences in the diabetes–cancer association.

Data availability The datasets generated during and/or analysed in the current study are available from the corresponding author on reasonable request.

Funding This study received no external funding. TO is supported by the John Chalmers Clinical Research Fellowship of the George Institute. SAEP is supported by a UK Medical Research Council Skills Development Fellowship (MR/P014550/1). MW is a National Health and Medical Research Council of Australia Principal Research Fellow.

Duality of interest MW is a consultant to Amgen. Both other authors declare that there is no duality of interest associated with their contribution to this manuscript.

Contribution statement TO searched the scientific literature, did the statistical analyses, participated in data interpretation and drafted the report. SAEP contributed data, did the statistical analyses, participated in data interpretation and made revisions to the draft report. MW conceived the study, contributed data, oversaw the data analyses, participated in data

interpretation and made revisions to the draft report. All authors gave final approval of the version to be published and are responsible for the integrity of the work as a whole. TO is the guarantor of this work.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. GBD 2015 Mortality and Causes of Death Collaborators (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 388:1459–1544
2. Fitzmaurice C, Allen C, Barber RM et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. *JAMA Oncol* 3:524–548
3. International Diabetes Federation (2015) IDF Diabetes Atlas, 7th edn. IDF, Brussels. Available from <https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventhedition.html>. Accessed 12 May 2018
4. Noto H, Tsujimoto T, Sasazuki T, Noda M (2011) Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. *Endocr Pract* 17:616–628
5. Ge Z, Ben Q, Qian J, Wang Y, Li Y (2011) Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. *Eur J Gastroenterol Hepatol* 23:1127–1135
6. Lee JY, Jeon I, Lee JM, Yoon JM, Park SM (2013) Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. *Eur J Cancer* 49:2411–2423
7. Bao C, Yang X, Xu W et al (2013) Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. *J Diabetes Complicat* 27:357–364
8. Huang W, Ren H, Ben Q, Cai Q, Zhu W, Li Z (2012) Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies. *Cancer Causes Control* 23:263–272
9. Kramer HU, Schottker B, Raum E, Brenner H (2012) Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. *Eur J Cancer* 48:1269–1282
10. Ben Q, Xu M, Ning X et al (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. *Eur J Cancer* 47:1928–1937
11. Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C (2013) Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. *BMC Cancer* 13:310
12. Schmid D, Behrens G, Jochem C, Keimling M, Leitzmann M (2013) Physical activity, diabetes, and risk of thyroid cancer: a systematic review and meta-analysis. *Eur J Epidemiol* 28:945–958
13. Wang Y, Wang B, Yan S et al (2016) Type 2 diabetes and gender differences in liver cancer by considering different confounding factors: a meta-analysis of cohort studies. *Ann Epidemiol* 26:764–772
14. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP (2015) Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. *BMJ* 350:g7607
15. Peters SA, Huxley RR, Woodward M (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic

- review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. *Lancet* 383:1973–1980
16. Peters SA, Huxley RR, Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia* 57:1542–1551
 17. Chatterjee S, Peters SA, Woodward M et al (2016) Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. *Diabetes Care* 39:300–307
 18. Lam EK, Batty GD, Huxley RR et al (2011) Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. *Ann Oncol* 22:730–738
 19. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 339:b2535
 20. Wells G, Shea B, O'Connell D et al. (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 17 Jun 2017
 21. Ragozzino M, Melton IHLJ, Chu CP, Palumbo PJ (1982) Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. *J Chronic Dis* 35:13–19
 22. Sasazuki S, Charvat H, Hara A et al (2013) Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. *Cancer Sci* 104:1499–1507
 23. Gini A, Bidoli E, Zanier L et al (2016) Cancer among patients with type 2 diabetes mellitus: a population-based cohort study in north-eastern Italy. *Cancer Epidemiol* 41:80–87
 24. Berger SM, Gislason G, Moore LL et al (2016) Associations between metabolic disorders and risk of cancer in Danish men and women—a nationwide cohort study. *BMC Cancer* 16:133
 25. Carstensen B, Read SH, Friis S et al (2016) Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. *Diabetologia* 59:980–988
 26. Hense HW, Kajuter H, Wellmann J, Batzler WU (2011) Cancer incidence in type 2 diabetes patients—first results from a feasibility study of the D2C cohort. *Diabetol Metab Syndr* 3:15
 27. Rapp K, Schroeder J, Klenk J et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. *Diabetologia* 49:945–952
 28. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. *JAMA* 293:194–202
 29. Wang M, Hu RY, Wu HB et al (2015) Cancer risk among patients with type 2 diabetes mellitus: a population-based prospective study in China. *Sci Rep* 5:11503
 30. Hsu PC, Lin WH, Kuo TH, Lee HM, Kuo C, Li CY (2015) A population-based cohort study of all-cause and site-specific cancer incidence among patients with type 1 diabetes mellitus in Taiwan. *J Epidemiol* 25:567–573
 31. Adami HO, McLaughlin J, Ekblom A et al (1991) Cancer risk in patients with diabetes mellitus. *Cancer Causes Control* 2:307–314
 32. Dankner R, Boffetta P, Balicer RD et al (2016) Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. *Am J Epidemiol* 183:1098–1106
 33. Lai GY, Park Y, Hartge P, Hollenbeck AR, Freedman ND (2013) The association between self-reported diabetes and cancer incidence in the NIH-AARP Diet and Health Study. *J Clin Endocrinol Metab* 98:E497–E502
 34. Xu HL, Fang H, Xu WH et al (2015) Cancer incidence in patients with type 2 diabetes mellitus: a population-based cohort study in Shanghai. *BMC Cancer* 15:852
 35. Oberaigner W, Ebenbichler C, Oberaigner K, Juchum M, Schonherr HR, Lechleitner M (2014) Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria. *BMC Public Health* 14:1058
 36. Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ (2015) Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. *Diabetes Care* 38:264–270
 37. Walker JJ, Brewster DH, Colhoun HM et al (2013) Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001–2007. *Diabetologia* 56:1712–1715
 38. Chodick G, Heymann AD, Rosenmann L et al (2010) Diabetes and risk of incident cancer: a large population-based cohort study in Israel. *Cancer Causes Control* 21:879–887
 39. Yeh HC, Platz EA, Wang NY, Visvanathan K, Helzlsouer KJ, Brancati FL (2012) A prospective study of the associations between treated diabetes and cancer outcomes. *Diabetes Care* 35:113–118
 40. Zhang PH, Chen ZW, Lv D et al (2012) Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. *BMC Public Health* 12:567
 41. Stattin P, Bjor O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. *Diabetes Care* 30:561–567
 42. Joshi CE, Prizment AE, Dlugiewski PJ et al (2012) Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990–2006. *Int J Cancer* 131:1667–1677
 43. Wideroff L, Gridley G, Mellekjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. *J Natl Cancer Inst* 89:1360–1365
 44. Bancks MP, Odegaard AO, Pankow JS et al (2014) Glycated hemoglobin and all-cause and cause-specific mortality in Singaporean Chinese without diagnosed diabetes: the Singapore Chinese Health Study. *Diabetes Care* 37:3180–3187
 45. Guzder RN, Gatling W, Mullee MA, Byrne CD (2007) Early mortality from the time of diagnosis of type 2 diabetes: a 5-year prospective cohort study with a local age- and sex-matched comparison cohort. *Diabet Med* 24:1164–1167
 46. Morimoto A, Onda Y, Nishimura R, Sano H, Utsunomiya K, Tajima N (2013) Cause-specific mortality trends in a nationwide population-based cohort of childhood-onset type 1 diabetes in Japan during 35 years of follow-up: the DERI Mortality Study. *Diabetologia* 56:2171–2175
 47. Swerdlow AJ, Laing SP, Dos Santos Silva I et al (2004) Mortality of South Asian patients with insulin-treated diabetes mellitus in the United Kingdom: a cohort study. *Diabet Med* 21:845–851
 48. Kato M, Noda M, Mizoue T et al (2015) Diagnosed diabetes and premature death among middle-aged Japanese: results from a large-scale population-based cohort study in Japan (JPHC study). *BMJ Open* 5:e007736
 49. Baena-Diez JM, Penafiel J, Subirana I et al (2016) Risk of cause-specific death in individuals with diabetes: a competing risks analysis. *Diabetes Care* 39:1987–1995
 50. Kang YM, Kim YJ, Park JY, Lee WJ, Jung CH (2016) Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013. *Cardiovasc Diabetol* 15:131
 51. Zhou XH, Qiao Q, Zethelius B et al (2010) Diabetes, prediabetes and cancer mortality. *Diabetologia* 53:1867–1876
 52. Tseng CH (2004) Mortality and causes of death in a national sample of diabetic patients in Taiwan. *Diabetes Care* 27:1605–1609
 53. Gnani R, Petrelli A, Demaria M, Spadea T, Carta Q, Costa G (2004) Mortality and educational level among diabetic and non-diabetic population in the Turin Longitudinal Study: a 9-year follow-up. *Int J Epidemiol* 33:864–871

54. Hirakawa Y, Ninomiya T, Mukai N et al (2012) Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study. *Am J Epidemiol* 176: 856–864
55. Forssas E, Sund R, Manderbacka K, Arffman M, Ilanne-Parikka P, Keskimäki I (2013) Increased cancer mortality in diabetic people treated with insulin: a register-based follow-up study. *BMC Health Serv Res* 13:267
56. Fedeli U, Zoppini G, Gennaro N, Saugo M (2014) Diabetes and cancer mortality: a multifaceted association. *Diabetes Res Clin Pract* 106:e86–e89
57. Gordon-Dseagu VL, Shelton N, Mindell J (2014) Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease: evidence from the Health Survey for England and Scottish Health Survey cohorts. *J Diabetes Complicat* 28:791–797
58. Shen C, Schooling CM, Chan WM, Lee SY, Leung GM, Lam TH (2014) Self-reported diabetes and mortality in a prospective Chinese elderly cohort study in Hong Kong. *Prev Med* 64:20–26
59. Weiderpass E, Gridley G, Nyren O, Pennello G, Landstrom AS, Ekblom A (2001) Cause-specific mortality in a cohort of patients with diabetes mellitus: a population-based study in Sweden. *J Clin Epidemiol* 54:802–809
60. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM (2012) Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. *Diabetes Care* 35:1835–1844
61. Verlato G, Zoppini G, Bonora E, Muggeo M (2003) Mortality from site-specific malignancies in type 2 diabetic patients from Verona. *Diabetes Care* 26:1047–1051
62. Sievers ML, Nelson RG, Knowler WC, Bennett PH (1992) Impact of NIDDM on mortality and causes of death in Pima Indians. *Diabetes Care* 15:1541–1549
63. Romon I, Rey G, Mandereau-Bruno L et al (2014) The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes—the 2001–2006 ENTRED cohort. *Diabet Med* 31:946–953
64. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ (2010) Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. *Diabetes* 59:3216–3222
65. Tierney EF, Geiss LS, Engelgau MM et al (2001) Population-based estimates of mortality associated with diabetes: use of a death certificate check box in North Dakota. *Am J Public Health* 91:84–92
66. Wong JS, Pearson DW, Murchison LE, Williams MJ, Narayan V (1991) Mortality in diabetes mellitus: experience of a geographically defined population. *Diabet Med* 8:135–139
67. Bruno G, Merletti F, Boffetta P et al (1999) Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus. *Diabetologia* 42:297–301
68. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ (1999) Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. *Diabetologia* 42:1050–1054
69. Moss SE, Klein R, Klein BE (1991) Cause-specific mortality in a population-based study of diabetes. *Am J Public Health* 81:1158–1162
70. Oba S, Nagata C, Nakamura K, Takatsuka N, Shimizu H (2008) Self-reported diabetes mellitus and risk of mortality from all causes, cardiovascular disease, and cancer in Takayama: a population-based prospective cohort study in Japan. *J Epidemiol* 18:197–203
71. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J (1990) Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. *Am J Epidemiol* 131:254–262
72. Idilbi NM, Barchana M, Milman U, Carel RS (2013) Incidence of cancer among diabetic and non-diabetic adult Israeli Arabs. *Isr Med Assoc J* 15:342–347
73. Hippisley-Cox J, Coupland C (2015) Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. *BMJ Open* 5:e007825
74. Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K (2010) Cancer risk among patients hospitalized for type 1 diabetes mellitus: a population-based cohort study in Sweden. *Diabet Med* 27:791–797
75. Lin CC, Chiang JH, Li CI et al (2014) Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in Taiwan. *BMC Cancer* 14:381
76. Xu HL, Tan YT, Epplein M et al (2015) Population-based cohort studies of type 2 diabetes and stomach cancer risk in Chinese men and women. *Cancer Sci* 106:294–298
77. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. *Cancer Epidemiol Biomark Prev* 13:915–919
78. Limburg PJ, Vierkant RA, Fredericksen ZS et al (2006) Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. *Am J Gastroenterol* 101:1872–1879
79. Schoen RE, Tangen CM, Kuller LH et al (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. *J Natl Cancer Inst* 91:1147–1154
80. Campbell PT, Deka A, Jacobs EJ et al (2010) Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. *Gastroenterology* 139:1138–1146
81. Goto A, Noda M, Sawada N et al (2016) High hemoglobin A1c levels within the non-diabetic range are associated with the risk of all cancers. *Int J Cancer* 138:1741–1753
82. Will JC, Galuska DA, Vinicor F, Calle EE (1998) Colorectal cancer: another complication of diabetes mellitus? *Am J Epidemiol* 147:816–825
83. Seow A, Yuan JM, Koh WP, Lee HP, Yu MC (2006) Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. *J Natl Cancer Inst* 98:135–138
84. Magliano DJ, Davis WA, Shaw JE, Bruce DG, Davis TM (2012) Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study. *Eur J Endocrinol* 167:589–599
85. Jarvandi S, Davidson NO, Schootman M (2013) Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality. *PLoS One* 8:e74616
86. Sikdar KC, Walsh SJ, Roche M, Jiang Y, Syrowatka A, Collins KD (2013) Diabetes and sex-specific colorectal cancer risks in Newfoundland and Labrador: a population-based retrospective cohort study. *Can J Public Health* 104:e101–e107
87. He J, Stram DO, Kolonel LN, Henderson BE, Le Marchand L, Haiman CA (2010) The association of diabetes with colorectal cancer risk: the Multiethnic Cohort. *Br J Cancer* 103:120–126
88. de Kort S, Simons CC, van den Brandt PA et al (2016) Diabetes mellitus type 2 and subsite-specific colorectal cancer risk in men and women: results from the Netherlands Cohort Study on diet and cancer. *Eur J Gastroenterol Hepatol* 28:896–903
89. Nilsen TI, Vatten LJ (2001) Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. *Br J Cancer* 84:417–422

90. Koskinen SV, Reunanen AR, Martelin TP, Valkonen T (1998) Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. *Am J Public Health* 88:765–770
91. Tan C, Mori M, Adachi Y et al (2016) Diabetes mellitus and risk of colorectal Cancer mortality in Japan: the Japan Collaborative Cohort Study. *Asian Pac J Cancer Prev* 17:4681–4688
92. Ren X, Zhang X, Zhang X et al (2009) Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. *Public Health* 123:540–544
93. Chen HF, Chen P, Su YH, Su HF, Li CY (2012) Age- and sex-specific risks of colorectal cancers in diabetic patients. *Tohoku J Exp Med* 226:259–265
94. Weiderpass E, Gridley G, Nyren O, Ekblom A, Persson I, Adami HO (1997) Diabetes mellitus and risk of large bowel cancer. *J Natl Cancer Inst* 89:660–661
95. Onitilo AA, Berg RL, Engel JM et al (2013) Increased risk of colon cancer in men in the pre-diabetes phase. *PLoS One* 8: e70426
96. Adami HO, Chow WH, Nyren O et al (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. *J Natl Cancer Inst* 88:1472–1477
97. Campbell PT, Newton CC, Freedman ND et al (2016) Body mass index, waist circumference, diabetes, and risk of liver Cancer for U.S. adults. *Cancer Res* 76:6076–6083
98. Yang WS, Shu XO, Gao J et al (2013) Prospective evaluation of type 2 diabetes mellitus on the risk of primary liver cancer in Chinese men and women. *Ann Oncol* 24:1679–1685
99. Koh WP, Wang R, Jin A, Yu MC, Yuan JM (2013) Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. *Br J Cancer* 108:1182–1188
100. Wild SH, Morling JR, McAllister DA et al (2016) Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. *J Hepatol* 64:1358–1364
101. Fujino Y, Mizoue T, Tokui N, Yoshimura T (2001) Prospective study of diabetes mellitus and liver cancer in Japan. *Diabetes Metab Res Rev* 17:374–379
102. Shibata A, Ogimoto I, Kurozawa Y et al (2003) Past medical history and risk of death due to hepatocellular carcinoma. univariate analysis of JACC study data. *Kurume Med J* 50:109–119
103. Chiang CH, Lee LT, Hung SH et al (2014) Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly. *Hepatology* 59:2207–2215
104. Chen HF, Chen P, Li CY (2010) Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications. *Hepatology* 52:155–163
105. Yagyu K, Lin Y, Obata Y et al (2004) Bowel movement frequency, medical history and the risk of gallbladder cancer death: a cohort study in Japan. *Cancer Sci* 95:674–678
106. Tsai MS, Lee PH, Lin CL, Peng CL, Kao CH (2015) Type II diabetes mellitus is associated with a reduced risk of cholangiocarcinoma in patients with biliary tract diseases. *Int J Cancer* 136: 2409–2417
107. Larsson SC, Permert J, Hakansson N, Naslund I, Bergkvist L, Wolke A (2005) Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. *Br J Cancer* 93:1310–1315
108. Nilsen TI, Vatten LJ (2000) A prospective study of lifestyle factors and the risk of pancreatic cancer in Nord-Trøndelag, Norway. *Cancer Causes Control* 11:645–652
109. Chow WH, Gridley G, Nyren O et al (1995) Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. *J Natl Cancer Inst* 87:930–931
110. Lin Y, Tamakoshi A, Kawamura T et al (2002) Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: findings from the Japan collaborative cohort study for evaluation of cancer risk. *Int J Cancer* 99:742–746
111. Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD (2005) Diabetes and the risk of lung cancer. *Diabetes Care* 28:590–594
112. Yang WS, Yang Y, Yang G et al (2014) Pre-existing type 2 diabetes and risk of lung cancer: a report from two prospective cohort studies of 133 024 Chinese adults in urban Shanghai. *BMJ Open* 4:e004875
113. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE (2007) Risk factors for renal cell cancer: the Multiethnic Cohort. *Am J Epidemiol* 166:932–940
114. Lindblad P, Chow WH, Chan J et al (1999) The role of diabetes mellitus in the aetiology of renal cell cancer. *Diabetologia* 42:107–112
115. Washio M, Mori M, Khan M et al (2007) Diabetes mellitus and kidney cancer risk: the results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study). *Int J Urol* 14:393–397
116. Goossens ME, Zeegers MP, Bazelier MT, De Bruin ML, Buntinx F, de Vries F (2015) Risk of bladder cancer in patients with diabetes: a retrospective cohort study. *BMJ Open* 5:e007470
117. Newton CC, Gapstur SM, Campbell PT, Jacobs EJ (2013) Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. *Int J Cancer* 132:2186–2191
118. Woolcott CG, Maskarinec G, Haiman CA, Henderson BE, Kolonel LN (2011) Diabetes and urothelial cancer risk: the Multiethnic Cohort study. *Cancer Epidemiol* 35:551–554
119. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. *Arch Intern Med* 166:1871–1877
120. Khan M, Mori M, Fujino Y et al (2006) Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. *Asian Pac J Cancer Prev* 7: 253–259
121. Khan AE, Gallo V, Linseisen J et al (2008) Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. *Haematologica* 93:842–850
122. Yang WS, Li HL, Xu HL et al (2016) Type 2 diabetes and the risk of non-Hodgkin's lymphoma: a report from two population-based cohort studies in China. *Eur J Cancer Prev* 25:149–154
123. Erber E, Lim U, Maskarinec G, Kolonel LN (2009) Common immune-related risk factors and incident non-Hodgkin lymphoma: the Multiethnic Cohort. *Int J Cancer* 125:1440–1445
124. Weiderpass E, Gridley G, Ekblom A, Nyren O, Hjalgrim H, Adami HO (1997) Medical history risk factors for non-Hodgkin's lymphoma in older women. *J Natl Cancer Inst* 89:816–817
125. Weiderpass E, Gridley G, Persson I, Nyren O, Ekblom A, Adami HO (1997) Risk of endometrial and breast cancer in patients with diabetes mellitus. *Int J Cancer* 71:360–363
126. Kitahara CM, Platz EA, Beane Freeman LE et al (2012) Physical activity, diabetes, and thyroid cancer risk: a pooled analysis of five prospective studies. *Cancer Causes Control* 23:463–471
127. Hemminki K, Forsti A, Sundquist K, Li X (2016) Cancer of unknown primary is associated with diabetes. *Eur J Cancer Prev* 25: 246–251
128. Kautzky-Willer A, Kamyar MR, Gerhat D et al (2010) Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. *Gend Med* 7:571–583
129. Pettitt DB, Klingensmith GJ, Bell RA et al (2009) Glycemic control in youth with diabetes: the SEARCH for Diabetes in Youth Study. *J Pediatr* 155:668–672.e661-663

130. Abe R, Yamagishi S (2008) AGE-RAGE system and carcinogenesis. *Curr Pharm Des* 14:940–945
131. Lorenzi M, Montisano DF, Toledo S, Barrioux A (1986) High glucose induces DNA damage in cultured human endothelial cells. *J Clin Invest* 77:322–325
132. Kramer HU, Raum E, Ruter G et al (2012) Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study. *Cardiovasc Diabetol* 11:88
133. Kirkman MS, Rowan-Martin MT, Levin R et al (2015) Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. *Diabetes Care* 38:604–609
134. Bertram MY, Vos T (2010) Quantifying the duration of pre-diabetes. *Aust N Z J Public Health* 34:311–314
135. Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. *Diabetes Care* 33:1674–1685
136. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P (2013) Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. *Prostate Cancer Prostatic Dis* 16:151–158
137. Uemura N, Okamoto S, Yamamoto S et al (2001) *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med* 345:784–789
138. Tsukuma H, Hiyama T, Tanaka S et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med* 328:1797–1801
139. Szmuiłowicz ED, Stuenkel CA, Seely EW (2009) Influence of menopause on diabetes and diabetes risk. *Nat Rev Endocrinol* 5: 553–558
140. Shapiro S (2007) Recent epidemiological evidence relevant to the clinical management of the menopause. *Climacteric* 10(Suppl 2): 2–15
141. Peters SA, Huxley RR, Woodward M (2013) Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. *Stroke* 44:2394–2401
142. Mongraw-Chaffin ML, Peters SA, Huxley RR, Woodward M (2015) The sex-specific association between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with 1.2 million participants. *Lancet Diabetes Endocrinol* 3:437–449